Related Experiment Videos
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy
1Department of Dermatology, Charité Clinic, Humboldt University, Schumannstr. 20-21, D-10117 Berlin, Germany. mworm@rz.charite.hu-berlin.de
The British Journal of Dermatology
|January 20, 1999
Summary
Systemic hypocomplementaemic urticarial vasculitis, a rare condition, often resists standard treatments. Cyclophosphamide-dexamethasone pulse therapy proved effective and well-tolerated in two patients, offering a new treatment option.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Systemic hypocomplementaemic urticarial vasculitis (SHUV) is a rare autoimmune disorder.
- SHUV is characterized by urticarial lesions, hypocomplementemia, and vasculitis.
- Treatment resistance is common with conventional immunosuppressive and immunomodulatory drugs.
Observation:
- Two female patients, aged 43 and 45, presented with SHUV.
- Both patients had previously shown unresponsiveness to multiple immunosuppressive and immunomodulatory therapies.
- Cyclophosphamide-dexamethasone pulse therapy was initiated for both individuals.
Findings:
- Cyclophosphamide-dexamethasone pulse therapy led to significant clinical improvement in both patients.
- The pulse therapy regimen was well-tolerated.
- No major adverse effects were reported during the treatment period.
Implications:
- Cyclophosphamide-dexamethasone pulse therapy demonstrates efficacy in managing refractory SHUV.
- This therapeutic approach offers a potentially valuable treatment strategy for SHUV.
- Further research into cyclophosphamide-dexamethasone pulse therapy for SHUV is warranted.